Synaffix BV is a clinical-stage biotech company that has established a proprietary antibody-drug conjugate (ADC) technology platform that enhances efficacy and tolerability. The company features technology offering (including 4 different ADC payloads) that enables the development of proprietary ADCs from any antibody, and a patent portfolio provides patent protection of resulting products through at least 2035. The company's technology employs an enzymatic modification of naturally occurring glycan anchor points found on all antibodies to enable efficient, site-specific, and stable conjugation of potent anti-cancer molecules using extensively optimized metal-free click chemistry, allowing clinicians to design complex biological drugs without the need for prior genetic modifications.
On-site & Remote